| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6861409 | NOVO | Growth hormone secretagogues |
Aug, 2022
(1 year, 8 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8192719 | NOVO | Methods and kits to diagnose growth hormone deficiency by oral administration of EP 1572 or EP 1573 compounds |
Oct, 2027
(3 years from now) | |
Macrilen is owned by Novo.
Macrilen contains Macimorelin Acetate.
Macrilen has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Macrilen are:
- US6861409
Macrilen was authorised for market use on 20 December, 2017.
Macrilen is available in for solution;oral dosage forms.
Macrilen can be used as a method for the diagnosis of adult growth hormone deficiency by measuring the level of growth hormone after oral administration of macimorelin.
Drug patent challenges can be filed against Macrilen from 20 December, 2021.
The generics of Macrilen are possible to be released after 12 October, 2027.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-170) | Dec 20, 2024 |
| New Chemical Entity Exclusivity(NCE) | Dec 20, 2022 |
Drugs and Companies using MACIMORELIN ACETATE ingredient
NCE-1 date: 20 December, 2021
Market Authorisation Date: 20 December, 2017
Treatment: A method for the diagnosis of adult growth hormone deficiency by measuring the level of growth hormone after oral administration of macimorelin
Dosage: FOR SOLUTION;ORAL
MACRILEN family patents
